← FDA Drug Approvals (Drugs@FDA)
ERYTHROMYCIN ETHYLSUCCINATE
ANDA · Abbreviated New Drug Application (Generic) · Sponsor: CADILA PHARMS LTD · Approved 2022-11-21
Drug application
- FDA Application #
ANDA216212- Application type
- Abbreviated New Drug Application (Generic)
- Brand name
- ERYTHROMYCIN ETHYLSUCCINATE
- Generic name
- ERYTHROMYCIN ETHYLSUCCINATE
- Active ingredients
- ERYTHROMYCIN ETHYLSUCCINATE
- Dosage form
- GRANULE
- Route
- ORAL
- Marketing status
- Prescription
- Sponsor
- CADILA PHARMS LTD
- Manufacturer
- Cadila Pharmaceuticals Limited
- First approval
- 2022-11-21
Source
- Authoritative
- Drugs@FDA application overview
- Machine
- JSON-LD · Markdown